Ulcerative colitis relapse seen in half of patients after tofacitinib dose reduction: study
Those who achieved endoscopic improvement but not remission were 'not protected' from losing response to JAK inhibitor
Half of patients with ulcerative colitis lose their remission response to tofacitinib after dose de-escalation, which is only “partially recaptured” with increasing maintenance dose, real-world data show.
Results from the largest cohort study to date also suggest that those with prior biologic failure and severe disease are at highest risk of losing response, according to Canadian doctors.
